Page 47 - Haematologica - Vol. 105 n. 6 - June 2020

CD20: functions and regulation
70. Pyrzynska B, Dwojak M, Zerrouqi A, et al. FOXO1 promotes resistance of non- Hodgkin lymphomas to anti-CD20-based therapy. Oncoimmunology. 2018;7(5): e1423183.
71. Trinh DL, Scott DW, Morin RD, et al. Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. Blood. 2013;121 (18):3666-3674.
72. Kelly KR, Friedberg JW, Park SI, et al. Phase I study of the investigational Aurora A kinase inhibitor alisertib plus rituximab or rituximab/vincristine in relapsed/refractory aggressive B-cell lymphoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2018;24(24):6150-6159.
73. Manfredi M. Combination of Aurora kinase inhibitors and anti-CD20 antibodies. US20100183601A1.
74. Tomita A, Hiraga J, Kiyoi H, et al. Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy. Int J Hematol. 2007;86(1):49-57.
75. Hiraga J, Tomita A, Sugimoto T, et al. Down-regulation of CD20 expression in B- cell lymphoma cells after treatment with rit- uximab-containing combination chemother- apies: its prevalence and clinical significance. Blood. 2009;113(20):4885-4893.
76. Sugimoto T, Tomita A, Hiraga J, et al. Escape mechanisms from antibody therapy to lym- phoma cells: downregulation of CD20 mRNA by recruitment of the HDAC com- plex and not by DNA methylation. Biochem Biophys Res Commun. 2009;390(1):48-53.
77. Tsutsumi Y, Ohigashi H, Ito S, Shiratori S, Teshima T. 5-Azacytidine partially restores CD20 expression in follicular lymphoma that lost CD20 expression after rituximab treatment: a case report. J Med Case Rep. 2016;10:27.
78. Damm JK, Gordon S, Ehinger M, et al. Pharmacologically relevant doses of val- proate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo. Exp Hematol Oncol. 2015;4:4.
79. Drott K, Hagberg H, Papworth K, Relander T, Jerkeman M. Valproate in combination with rituximab and CHOP as first-line ther- apy in diffuse large B-cell lymphoma (VAL- FRID). Blood Adv. 2018;2(12):1386-1392.
80. Scialdone A, Hasni MS, Damm JK, Lennartsson A, Gullberg U, Drott K. The HDAC inhibitor valproate induces a biva- lent status of the CD20 promoter in CLL patients suggesting distinct epigenetic regu- lation of CD20 expression in CLL in vivo. Oncotarget. 2017;8(23):37409-37422.
81. Frys S, Simons Z, Hu Q, et al. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti- tumour activity of rituximab and chemotherapy agents. Br J Haematol. 2015;169(4):506-519.
82. Bobrowicz M, Dwojak M, Pyrzynska B, et al. HDAC6 inhibition upregulates CD20 lev- els and increases the efficacy of anti-CD20 monoclonal antibodies. Blood. 2017;130(14): 1628-1638.
83. Gagez A-L, Duroux-Richard I, Leprêtre S, et al. miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphode- pletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study. Haematologica. 2017;102 (4):746-754.
84. Williams ME, Densmore JJ, Pawluczkowycz AW, et al. Thrice-weekly low-dose ritux- imab decreases CD20 loss via shaving and promotes enhanced targeting in chronic
lymphocytic leukemia. J Immunol. 2006;177
(10):7435-7443.
85. Baig NA, Taylor RP, Lindorfer MA, et al.
Induced resistance to ofatumumab-mediat- ed cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia. J Immunol. 2014;192(4):1620-1629.
86. Beers SA, French RR, Chan HTC, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for anti- body selection. Blood. 2010;115(25):5191- 5201.
87. Niederfellner G, Lammens A, Mundigl O, et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood. 2011;118(2):358- 367.
88. Deans JP, Robbins SM, Polyak MJ, Savage JA. Rapid redistribution of CD20 to a low density detergent-insoluble membrane com- partment. J Biol Chem. 1998;273(1):344-348.
89. Chan HTC, Hughes D, French RR, et al. CD20-induced lymphoma cell death is inde- pendent of both caspases and its redistribu- tion into triton X-100 insoluble membrane rafts. Cancer Res. 2003;63(17):5480-5489.
90. Lim SH, Vaughan AT, Ashton-Key M, et al. Fc gamma receptor IIb on target B cells pro- motes rituximab internalization and reduces clinical efficacy. Blood. 2011;118(9):2530- 2540.
91. Johnson NA, Leach S, Woolcock B, et al. CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lym- phomas and are not a significant cause of R- CHOP failure. Haematologica. 2009;94(3): 423-427.
92. Terui Y, Mishima Y, Sugimura N, et al. Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin’s lymphoma. Clin Cancer Res. 2009;15(7):2523-2530.
93. Nakamaki T, Fukuchi K, Nakashima H, et al. CD20 gene deletion causes a CD20-negative relapse in diffuse large B-cell lymphoma. Eur J Haematol. 2012;89(4):350-355.
94. Stilgenbauer S, Schnaiter A, Paschka P, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014;123(21):3247- 3254.
95. Pozzo F, Bittolo T, Arruga F, et al. NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dys- regulation. Leukemia. 2016;30(1):182-189.
96. Buchner M, Brantner P, Stickel N, et al. The microenvironment differentially impairs passive and active immunotherapy in chron- ic lymphocytic leukaemia - CXCR4 antago- nists as potential adjuvants for monoclonal antibodies. Br J Haematol. 2010;151(2):167- 178.
97. Mraz M, Zent CS, Church AK, et al. Bone marrow stromal cells protect lymphoma B- cells from rituximab-induced apoptosis and targeting integrin alfa-4-beta-1 (VLA-4) with natalizumab can overcome this resistance. Br J Haematol. 2011;155(1):53-64.
98. Anolik J, Looney RJ, Bottaro A, Sanz I, Young F. Down-regulation of CD20 on B cells upon CD40 activation. Eur J Immunol. 2003;33(9):2398-2409.
99. Kawabata KC, Ehata S, Komuro A, Takeuchi K, Miyazono K. TGF- -induced apoptosis of B-cell lymphoma Ramos cells through reduction of MS4A1/CD20. Oncogene. 2013;32(16):2096-2106.
100. Skarzynski M, Niemann CU, Lee YS, et al. Interactions between ibrutinib and anti-
CD20 antibodies: competing effects on the outcome of combination therapy. Clin Cancer. 2016;22(1):86-95.
101. van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB. Complement- induced cell death by rituximab depends on CD20 expression level and acts complemen- tary to antibody-dependent cellular cytotox- icity. Clin Cancer Res. 2006;12(13):4027- 4035.
102. Bao Y, Zheng J, Han C, et al. Correction: Tyrosine kinase Btk is required for NK cell activation. J Biol Chem. 2020;295(10):3389.
103. Khurana D, Arneson LN, Schoon RA, Dick CJ, Leibson PJ. Differential regulation of human NK cell-mediated cytotoxicity by the tyrosine kinase Itk. J Immunol. 2007;178(6):3575-3582.
104. Da Roit F, Engelberts PJ, Taylor RP, et al. Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. Haematologica. 2015;100(1):77-86.
105. Kohrt HE, Sagiv-Barfi I, Rafiq S, et al. Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood. 2014;123(12):1957-1960.
106. Chu CC, Pinney JJ, VanDerMeid KR, et al. Anti-CD20 therapy reliance on antibody- dependent cellular phagocytosis affects combination drug choice. Blood. 2019;134 (Supplement_1):682-682.
107. Jaglowski SM, Jones JA, Nagar V, et al. Safety and activity of BTK inhibitor ibruti- nib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. Blood. 2015;126(7):842-850.
108. Golay J, Ubiali G, Introna M. The specific Bruton tyrosine kinase inhibitor acalabruti- nib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies. Haematologica. 2017;102(10):e400-e403.
109. Sharman JP, Banerji V, Fogliatto LM, et al. ELEVATE TN: Phase 3 study of acalabrutinib combined with obinutuzumab (O) or alone vs o plus chlorambucil (Clb) in patients (Pts) with treatment-naive chronic lymphocytic leukemia (CLL). Blood. 2019;134 (Suppl 1):31.
110. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997-1007.
111. Jones JA, Robak T, Brown JR, et al. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, ran- domised phase 3 trial. Lancet Haematol. 2017;4(3):e114-e126.
112. Winiarska M, Bojarczuk K, Pyrzynska B, et al. Inhibitors of SRC kinases impair antitu- mor activity of anti-CD20 monoclonal anti- bodies. mAbs. 2014;6(5):1300-1313.
113. Bojarczuk K, Siernicka M, Dwojak M, et al. B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies. Leukemia. 2014;28(5):1163-1167.
114. Guo H, Samarakoon A, Vanhaesebroeck B, Malarkannan S. The p110 delta of PI3K plays a critical role in NK cell terminal mat- uration and cytokine/chemokine generation. J Exp Med. 2008;205(10):2419-2435.
115. Herman SEM, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activ- ity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010;116(12):2078- 2088.
116. Fischer K, Al-Sawaf O, Bahlo J, et al.
haematologica | 2020; 105(6)
1505